Real-life data and learning from practice to advance innovation

[1]  J. McGinnis,et al.  Evidence-based medicine - engineering the Learning Healthcare System. , 2010, Studies in health technology and informatics.

[2]  Liam Smeeth,et al.  Validity of diagnoses in the general practice research database. , 2011, The British journal of general practice : the journal of the Royal College of General Practitioners.

[3]  Frank de Vries,et al.  Reanalysis of two studies with contrasting results on the association between statin use and fracture risk: the General Practice Research Database. , 2006, International journal of epidemiology.

[4]  T. V. van Staa,et al.  Recent advances in the utility and use of the General Practice Research Database as an example of a UK Primary Care Data resource , 2012, Therapeutic advances in drug safety.

[5]  Paul Wallace,et al.  Use of electronic patient records for research: views of patients and staff in general practice. , 2013, Family practice.

[6]  L. Smeeth,et al.  Randomised Evaluations of Accepted Choices in Treatment (REACT) trials: large-scale pragmatic trials within databases of routinely collected electronic healthcare records , 2011, Trials.

[7]  F A Boddy,et al.  Using routine data to complement and enhance the results of randomised controlled trials. , 2000, Health technology assessment.

[8]  H. Sørensen,et al.  The Nordic countries as a cohort for pharmacoepidemiological research. , 2010, Basic & clinical pharmacology & toxicology.

[9]  A. Porsius,et al.  Suboptimal choices and dosing of statins at start of therapy. , 2005, British journal of clinical pharmacology.

[10]  D. Altman,et al.  Waiving confidentiality for the greater good , 2006, BMJ : British Medical Journal.

[11]  L. Yardley,et al.  Cluster randomised trial in the General Practice Research Database: 1. Electronic decision support to reduce antibiotic prescribing in primary care (eCRT study) , 2011, Trials.

[12]  Dipak Kalra,et al.  Confidentiality of personal health information used for research , 2006, BMJ : British Medical Journal.

[13]  P. Rothwell,et al.  External validity of randomised controlled trials: “To whom do the results of this trial apply?” , 2005, The Lancet.

[14]  B. Stricker,et al.  Recruitment of participants through community pharmacies for a pharmacogenetic study of antihypertensive drug treatment , 2009, Pharmacy World & Science.

[15]  David Atkins,et al.  Good research practices for comparative effectiveness research: defining, reporting and interpreting nonrandomized studies of treatment effects using secondary data sources: the ISPOR Good Research Practices for Retrospective Database Analysis Task Force Report--Part I. , 2009, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[16]  David Atkins,et al.  Practices for Comparative Effectiveness Research : Defining , Reporting and Interpreting Nonrandomized Studies of Treatment Effects Using Secondary Data Sources : The ISPOR Good Research Practices for Retrospective Database Analysis Task Force Report — Part , 2009 .

[17]  J. Hippisley-Cox,et al.  Derivation and validation of QRISK, a new cardiovascular disease risk score for the United Kingdom: prospective open cohort study , 2007, BMJ : British Medical Journal.

[18]  T. MacDonald,et al.  Cluster randomized trials of prescription medicines or prescribing policy: public and general practitioner opinions in Scotland , 2012, British journal of clinical pharmacology.

[19]  David L Buckeridge,et al.  Drug, patient, and physician characteristics associated with off-label prescribing in primary care. , 2012, Archives of internal medicine.

[20]  J. Ioannidis.  Mega-trials for blockbusters. , 2013, JAMA.

[21]  T. MacDonald,et al.  Managing security and privacy concerns over data storage in healthcare research , 2011, Pharmacoepidemiology and drug safety.

[22]  S. Cummings,et al.  Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures , 1996, The Lancet.

[23]  Wiebe R. Pestman,et al.  Instrumental Variables: Application and Limitations , 2006, Epidemiology.

[24]  Ian Harvey,et al.  A pragmatic-explanatory continuum indicator summary (PRECIS): a tool to help trial designers. , 2009, Journal of clinical epidemiology.

[25]  B. Psaty,et al.  Is Drug Treatment of Hypertension in Clinical Practice as Effective as in Randomized Controlled Trials with Regard to the Reduction of the Incidence of Stroke? , 2001, Epidemiology.

[26]  P. Souverein,et al.  Society already achieves economic benefits from generic substitution but fails to do the same for therapeutic substitution. , 2007, British journal of clinical pharmacology.

[27]  H. Eichler,et al.  Adaptive Licensing: Taking the Next Step in the Evolution of Drug Approval , 2012, Clinical pharmacology and therapeutics.

[28]  Dominique L. Monnet,et al.  Priority Medicines for Europe and the World , 2005 .

[29]  Heather M. Tavel,et al.  Comparative Effectiveness of 2 -Blockers in Hypertensive Patients , 2012 .

[30]  Melissa C Brouwers,et al.  Written informed consent and selection bias in observational studies using medical records: systematic review , 2009, BMJ : British Medical Journal.

[31]  N. Terry,et al.  The Emergence of National Electronic Health Record Architectures in the United States and Australia: Models, Costs, and Questions , 2005, Journal of medical Internet research.

[32]  H. Hemingway,et al.  Clopidogrel discontinuation after acute coronary syndromes: frequency, predictors and associations with death and myocardial infarction—a hospital registry-primary care linked cohort (MINAP–GPRD) , 2011, European heart journal.

[33]  Lixia Yao,et al.  Electronic health records: Implications for drug discovery. , 2011, Drug discovery today.

[34]  J. Ioannidis,et al.  Comparison of evidence of treatment effects in randomized and nonrandomized studies. , 2001, JAMA.

[35]  H. Leufkens,et al.  Changes in the characteristics of patients prescribed selective cyclooxygenase 2 inhibitors after the 2004 withdrawal of rofecoxib. , 2008, Arthritis and rheumatism.

[36]  I Persson,et al.  What is the harm-benefit ratio of Cox-2 inhibitors? , 2008, International journal of epidemiology.

[37]  Albert-László Barabási,et al.  A Dynamic Network Approach for the Study of Human Phenotypes , 2009, PLoS Comput. Biol..

[38]  Su Golder,et al.  Meta-analyses of Adverse Effects Data Derived from Randomised Controlled Trials as Compared to Observational Studies: Methodological Overview , 2011, PLoS medicine.

[39]  A. Gallagher,et al.  Cancer recording and mortality in the General Practice Research Database and linked cancer registries , 2013, Pharmacoepidemiology and drug safety.

[40]  Jan P Vandenbroucke,et al.  When are observational studies as credible as randomised trials? , 2004, The Lancet.

[41]  Sean D Sullivan,et al.  Methods to assess intended effects of drug treatment in observational studies are reviewed. , 2004, Journal of clinical epidemiology.

[42]  L. Smeeth,et al.  A Comparison of Cost Effectiveness Using Data from Randomized Trials or Actual Clinical Practice: Selective Cox-2 Inhibitors as an Example , 2009, PLoS medicine.

[43]  Roger Collier,et al.  Rapidly rising clinical trial costs worry researchers , 2009, Canadian Medical Association Journal.

[44]  Chunhua Weng,et al.  Methods and dimensions of electronic health record data quality assessment: enabling reuse for clinical research , 2013, J. Am. Medical Informatics Assoc..

[45]  K. Verhamme,et al.  Drug use in children: cohort study in three European countries , 2008, BMJ : British Medical Journal.

[46]  S. Jick,et al.  Use of Antidiabetic Agents and the Risk of Pancreatic Cancer: A Case–Control Analysis , 2012, The American Journal of Gastroenterology.

[47]  R. Makuch,et al.  Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. , 2000, JAMA.

[48]  S. Rietbrock,et al.  Fracture Outcomes Related to Persistence and Compliance With Oral Bisphosphonates , 2008, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[49]  M. Schuemie,et al.  Combining electronic healthcare databases in Europe to allow for large‐scale drug safety monitoring: the EU‐ADR Project , 2011, Pharmacoepidemiology and drug safety.